Acute Myeloid Leukemia: A focus on Risk Factors, Clinical Presentation, Diagnosis and Possible Lines of Management

Ahmed M. Kabel^{1, 2,} , Ftoon Zamzami³, Manal Al-Talhi³, Khairiyah Al-Dwila³ and Reham Hamza³

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA

²Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

³Final year student, College of Pharmacy, Taif University, Taif, KSA

Cite this paper:
Ahmed M. Kabel, Ftoon Zamzami, Manal Al-Talhi, Khairiyah Al-Dwila and Reham Hamza. Acute Myeloid Leukemia: A focus on Risk Factors, Clinical Presentation, Diagnosis and Possible Lines of Management. Journal of Cancer Research and Treatment. 2017; 5(2):62-67. doi: 10.12691/jcrt-5-2-4

Abstract

The aim of this review was to shed light on the epidemiology, classification, possible risk factors, clinical presentation, diagnosis and possible lines of management of acute myeloid leukemia (AML). AML is one of the malignancies originating from the myeloid line of blood cells. It is characterized by rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with production of normal blood cells. It is the most common acute leukemia affecting adults, and its incidence increases with age. Several risk factors and chromosomal abnormalities have been identified in AML. AML has several subtypes which determine the suitable lines of treatment and the overall prognosis. AML involves a high percentage of dedifferentiated and undifferentiated cells, including more myeloblasts, monoblasts and megakaryoblasts. Symptoms of AML are variable, including fatigue, shortness of breath, easy bruising and bleeding with increased risk of infections. AML is treated initially with chemotherapy to induce remission. Then, patients may receive additional chemotherapy or hematopoietic stem cell transplantation. In conclusion, AML is the most common type of acute leukemia in adults which is usually precipitated by mutations in the genes involved in hematopoietic proliferation and differentiation and its main lines of treatment remain combination of cytarabine- and anthracycline-based regimens with allogeneic stem cell transplantation for eligible patients.

Keywords:
myeloid leukemia risk factors diagnosis management

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Adwas AA, Elkhoely AA, Kabel AM, Abdel-Rahman MN, Eissa AA. Anti-cancer and cardioprotective effects of indol-3-carbinol in doxorubicin-treated mice. J Infect Chemother. 2016; 22 (1): 36-43.
[2]	Sill H, Olipitz W, Zebisch A, Schulz E, Wolfler A. Therapy-related myeloid neoplasms: Pathobiology and clinical characteristics. Br J Pharmacol 2011; 162; 792-805.
[3]	De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 2016; 6(7): e441.
[4]	Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol 2015; 33(31): 3641-9.
[5]	Hasserjian RP. Acute myeloid leukemia: advances in diagnosis and classification. Int J Lab Hematol 2013; 35(3): 358-66.
[6]	Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 2005; 32(4 Suppl 5): S3-10.
[7]	Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: rationale and important changes. Blood 2009; 114(5): 937-51.
[8]	Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391-405.
[9]	Rampal R, Mascarenhas J. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Curr Opin Hematol 2014; 21(2): 65-71.
[10]	Tallarico M, Odenike O. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies. Curr Hematol Malig Rep 2015; 10(2): 112-7.
[11]	Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87(1): 89-99.
[12]	Hassler A1, Bochennek K1, Gilfert J, et al. Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. Pediatr Blood Cancer. 2016; 63(6): 1070-4.
[13]	Gray TL, Ooi CY, Tran D, et al. Gastrointestinal complications in children with acute myeloid leukemia. Leuk Lymphoma. 2010; 51(5): 768-77.
[14]	Nickels EM, Soodalter J, Churpek JE, Godley LA. Recognizing familial myeloid leukemia in adults. Therapeutic Advances in Hematology 2013;4(4):254-69.
[15]	Kazemi F, Najafabadi TA, Araabi BN. Automatic Recognition of Acute Myelogenous Leukemia in Blood Microscopic Images Using K-means Clustering and Support Vector Machine. Journal of Medical Signals and Sensors 2016; 6(3): 183-93.
[16]	Salem DA, Abd El-Aziz SM. Flowcytometric Immunophenotypic Profile of Acute Leukemia: Mansoura Experience. Indian J Hematol Blood Transfus 2012; 28(2):89-96.
[17]	Souto Filho JTD, Loureiro MM, Pulcheri W, Morais JC, Nucci M, Portugal RD. Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy. Diagnostic Pathology 2015; 10: 122.
[18]	Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 43-50.
[19]	Tasaki T, Yamauchi T, Matsuda Y, et al. The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience. Anticancer Res 2014; 34(10): 5631-6.
[20]	Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica. 2014; 99(11): 1663-70.
[21]	Ali N, Adil SN, Shaikh MU, Masood N. Allogeneic stem cell transplantation in acute myeloid leukemia. Hematology Reports 2012; 4(4): e25.
[22]	Heiblig M, Elhamri M, Tigaud I, et al. Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience. Mediterranean Journal of Hematology and Infectious Diseases 2016; 8(1): e2016009.
[23]	Prakash B. Treatment of relapsed undifferentiated acute myeloid leukemia (AML-M0) with Ayurvedic therapy. Int J Ayurveda Res 2011; 2(1): 56-9.
[24]	Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol 2017; 18(3): 17.
[25]	Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27(32): 5397- 403.
[26]	Bittencourt R, Bortolheiro TC, de Lourdes Lopes Ferrari Chauffaille M, et al. Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira – 2015. Revista Brasileira de Hematologia e Hemoterapia 2016; 38(1): 58-74.
[27]	Li W, Gong X, Sun M, et al. High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis. Lam W, ed. PLoS ONE 2014; 9(10): e110153.
[28]	Zeidan AM, Gore SD. New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach. Clinical cancer research: an official journal of the American Association for Cancer Research 2014; 20(19): 4985-93.
[29]	Cull EH, Altman JK. Contemporary treatment of APL. Curr Hematol Malig Rep. 2014; 9(2):193-201.
[30]	Zimmermann C, Yuen D, Mischitelle A, et al. Symptom burden and supportive care in patients with acute leukemia. Leukemia research 2013; 37(7):10.
[31]	Kabel AM, Abd Elmaaboud MA. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. World Journal of Nutrition and Health 2014; 2(4): 48-51.
[32]	Caldwell JT, Ge Y, Taub JW. Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert review of hematology 2014;7(6):831-40.
[33]	Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016; 374(23): 2209-21.
[34]	Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol 2009; 27: 2668-76.
[35]	Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145: 318-32.